Evaluating and improving the quality of risperidone prescribing
Open Access
- 1 November 1997
- journal article
- Published by Royal College of Psychiatrists in Psychiatric Bulletin
- Vol. 21 (11) , 680-683
- https://doi.org/10.1192/pb.21.11.680
Abstract
Clinical studies suggest that risperidone is an effective antipsychotic with a low incidence of extrapyramidal adverse effects. In a prescription survey of several trusts, we found that risperidone was widely prescribed at high doses alongside typical neuroleptics and anticholinergic drugs. We also demonstrated that prescribing in a single trust can be improved by simple interventions. Risperidone should be prescribed as the sole antipsychotic at doses below 8 mg/day to realise fully its clinical advantages. Few prescriptions met this standard.Keywords
This publication has 13 references indexed in Scilit:
- Antipsychotic dose: from research to clinical practicePsychiatric Bulletin, 1996
- Risperidone response after no clozapine responseThe British Journal of Psychiatry, 1995
- Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus HaloperidolThe British Journal of Psychiatry, 1995
- Risperidone in the treatment of schizophreniaAmerican Journal of Psychiatry, 1994
- The Use of High-Dose Antipsychotic MedicationThe British Journal of Psychiatry, 1994
- RisperidoneThe Lancet, 1994
- Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative studyActa Psychiatrica Scandinavica, 1992
- Time course of antipsychotic effects of neuroleptic drugsAmerican Journal of Psychiatry, 1989
- Clozapine for the Treatment-Resistant SchizophrenicArchives of General Psychiatry, 1988